Multimodality Therapy
Thoracic Oncology

Get to Know Dr. Corey J. Langer

Medical oncologist Dr. Corey Langer has helped the Abramson Cancer Center become a leader in advancing the treatment of thoracic malignancies, utilizing the most sophisticated, advanced-science technology.

He is also a professor of medicine at the Hospital of the University of Pennsylvania, where he has clinical expertise in a wide range of malignancies.

Langer believes there is no better place for a patient than Abramson, where he plays a role in the Lung Cancer Program, the Mesothelioma and Pleural Disease Program and the Center for Head and Neck Cancer. Each takes a comprehensive, multidisciplinary approach to treatment.

His research has focused on novel alternative treatments, particularly those that have helped the elderly and others with limited functionality. His expertise also revolves around multimodality therapy for locally advanced disease.

Langer encourages an open, easy-to-understand dialogue with patients, believing a small, community-centered flavor can add to a large, state-of-the-art cancer center.

Specialties of Dr. Corey J. Langer

  • Mesothelioma
  • Lung cancer
  • Head and neck cancer
  • Immunotherapy
  • Esophageal cancer
  • Head and neck melanoma

Dr. Corey J. Langer’s Experience and Medical Education

  • Penn Medicine’s Abramson Cancer Center
  • Fox Chase Cancer Center; Penn Presbyterian Medical Center (Fellowships)
  • Graduate Hospital (Residency)
  • Boston University School of Medicine (M.D.)

Awards and Certifications

  • America’s Top Doctors
  • Best Doctors in America
  • Top Doctors, Philadelphia magazine
  • Board certified, medical oncology
  • Board certified, internal medicine

Mesothelioma Clinical Trials Under Corey J. Langer, M.D.

  • A phase III clinical trial evaluating the safety and efficacy of intrapleural administration of adenovirus-delivered interferon Alpha-2b, known as rAd-IFN) in combination with celecoxib and gemcitabine for malignant pleural mesothelioma.
  • A phase I clinical trial studying the safety and preliminary efficacy of adding pembrolizumab, also known by the brand name Keytruda, to a combination of chemotherapy and surgical resection for patients with pleural mesothelioma.

Publications of Dr. Corey J. Langer

  • Aggarwal, C. et al. (2019, October). Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncology.
  • Langer, C.J. et al. (2019, October). SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal of Thoracic Oncology.
  • Gubens, M.A., et al. (2019, April). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer.